anti-CD5 immunotoxin H65 (scFv)-RTA (CAT#: AGTO-L053R)
This immunotoxin was achieved by conjugating/fusing the Anti-CD5 scFv to ricin A chain. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to T cells which express the CD5 antigen. Then the ricin A chain is incorporated into the cell by receptor-mediated endocytosis, blocking ribosomal protein synthesis and ultimately leading to cell death. It was designed for treatment of T cell leukemias or lymphomas, graft-versus-host diseases, and autoimmune diseases.
Specific Inquiry
Custom Production
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.
We require custom production
Normal Tissue
RNA Expression
Figure 1 Testis
(Spermatogonia cells
Staining: Medium
Intensity: Moderate
Quantity: 75%-25%)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/43416/101306_A_5_6.jpg
(Spermatogonia cells
Staining: Medium
Intensity: Moderate
Quantity: 75%-25%)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/43416/101306_A_5_6.jpg
Figure 2 Lymph node
(Germinal center cells
Staining: Medium
Intensity: Strong
Quantity: <25%
Location: Cytoplasmic/membranous
Non-germinal center cells
Staining: High
Intensity: Strong
Quantity: 75%-25%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/43416/101306_A_7_8.jpg
(Germinal center cells
Staining: Medium
Intensity: Strong
Quantity: <25%
Location: Cytoplasmic/membranous
Non-germinal center cells
Staining: High
Intensity: Strong
Quantity: 75%-25%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/43416/101306_A_7_8.jpg
Figure 3 Tonsil
(Germinal center cells
Staining: Medium
Intensity: Strong
Quantity: <25%
Location: Cytoplasmic/membranous
Non-germinal center cells
Staining: High
Intensity: Strong
Quantity: 75%-25%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/43416/101306_A_5_8.jpg
(Germinal center cells
Staining: Medium
Intensity: Strong
Quantity: <25%
Location: Cytoplasmic/membranous
Non-germinal center cells
Staining: High
Intensity: Strong
Quantity: 75%-25%
Location: Cytoplasmic/membranous)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/images/43416/101306_A_5_8.jpg
Figure 4 RNA cell line category: Group enriched (JURKAT, MOLT-4)
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000110448-CD5
(Cell lines ordered by descending RNA expression order.)
* Image credit: Human Protein Atlas https://v21.proteinatlas.org/ENSG00000110448-CD5
Specifications
- Host Species
- Mouse
- Species Reactivity
- Human
- Clone
- H65
- Molecule Class
- scFv-RTA
- Toxin Description
- Ricin consist of two polypeptide chains, A and B, linked by means of disulfide bridge(s). Cytotoxicity is associated with the A chain and its 15 inhibition of protein synthesis in nucleated cells. The B chain is essentially a delivery vehicle for the A chain. The B chain recognizes polysaccharide units at the surface of cells and creates a high affinity interaction with such units. Once the B chain binds with polysaccharide units at 20" the celL surface, the A chain is incorporated into the cell, blocking ribosomal protein synthesis and ultimately leading tocell death. The use of ricin A chain is preferred in this invention.
- Applications
- This product is suitable for use in cytotoxicity assay, functional assay and immunotherapy.
- Related Disease
- T cell leukemias or lymphomas, graft- versus-host diseases, and autoimmune diseases
Target
- Alternative Names
- CD5; CD5 molecule; T1; LEU1; T-cell surface glycoprotein CD5; CD5 antigen (p56-62); lymphocyte antigen T1/Leu-1; T cell leukemias; lymphomas; graft- versus-host diseases; autoimmune diseases; Deglycosylated ricin A chain; Ricin A chain; Ricin A; Ricin; RTA; RT; RA; dgRTA; dgRA; dgA
- Gene ID
- 921
- UniProt ID
- P06127
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Clone H65"
See other products for "CD5"
Select a product category from the dropdown menu below to view related products.
Please select product type
Mouse Antibodies
Immunotoxins
Chimeric Antibodies
Blocking Antibodies
Rabbit Monoclonal Antibodies
ScFv Antibodies
Fab Antibodies
IgG Antibodies
Antibody Magnetic Beads
NHP Antibodies
FC Reagents & Kits
ScFv-Fc Chimeras
Extracellular Vesicle Antibodies
IHC Kits & Antibodies
| CAT | Product Name | Application | Type |
|---|---|---|---|
| TAB-884 | Mouse Anti-CD5 Recombinant Antibody (clone Zolimomab) | IP, IF, FuncS, FC, Neut, ELISA, ICC | Mouse IgG1 |
| TAB-885 | Mouse Anti-CD5 Recombinant Antibody (clone Telimomab); Fab Fragment | FuncS, IF, Neut, ELISA, FC, IP, ICC | Mouse Fab |
| TAB-308LC | Anti-Human CD5 Recombinant Antibody (5D7) | Cyt, FC, FuncS | |
| TAB-308LC-S(P) | Anti-Human CD5 Recombinant Antibody scFv Fragment (5D7) | FC, SPR | |
| TAB-308LC-F(E) | Anti-Human CD5 Recombinant Antibody Fab Fragment (5D7) | FC, SPR |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for AGTO-L053R. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: FC, IP, ELISA, Neut, FuncS, IF, ICC
Application: WB, Neut, FuncS
Application: WB, ELISA, Neut, FuncS
Application: ELISA, FC, IHC, Neut
For Research Use Only. Not For Clinical Use.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
